Lecozotan

Lecozotan
Systematic (IUPAC) name
	4-Cyano-N-[(2R)-2-[4-(2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperazinyl]propyl]-N-2-pyridinylbenzamide hydrochloride
Clinical data
Pregnancy cat.	?
Legal status	?
Identifiers
CAS number	434283-16-6
ATC code	None
PubChem	CID 11156648
UNII	48854OTZ5E
KEGG	D04683
Chemical data
Formula	C28H30ClN5O3
Mol. mass	520.021 g/mol
SMILES	eMolecules & PubChem
(what is this?) (verify);

From Wikipedia, the free encyclopedia

Jump to: navigation, search

Lecozotan is an investigational drug by Wyeth tested for improvement of cognitive functions of Alzheimer's disease patients.^[1] As of June 2008^[update], the first Phase III clinical trial has been completed.^[2]

[edit] Method of action

Lecozotan is a competitive, selective 5-HT_1A receptor antagonist^[3] which enhances the potassium-stimulated release of acetylcholine and glutamate.^[4]

^ H. Spreitzer (August 13, 2008). "Neue Wirkstoffe - Lecozotan" (in German). Österreichische Apothekerzeitung (17/2007): 805.
^ ClinicalTrials
^ Schlechter, LE; Smith, DL; Rosenzweig-Lipson, S; Sukoff, SJ; Dawson, LA; Marquis, K; Jones, D; Piesla, M et al. (June 10, 2005). "Lecotozan (SRA-333): A selective serotonin1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and promotes procognitive effects". Journal of Pharmacology and Experimental Therapeutics 314 (3): 1274. doi:10.1124/jpet.105.086363. PMID 15951399. http://jpet.aspetjournals.org/cgi/content/short/jpet.105.086363v1.
^ Childers, WE Jr, Harrison, BL, Abou-Gharbia, MA, Raje, S, Parks, V, Pangalos, MN, Schechter, LE (2007). "Lecozotan Hydrochloride". Drugs of the Future 32 (5): 399–407. doi:10.1358/dof.2007.032.05.1092901. http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=1092901&p_IsPs=N.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.